nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrimeprazine—DRD5—attention deficit hyperactivity disorder	0.187	0.234	CbGaD
Methotrimeprazine—ADRA2C—attention deficit hyperactivity disorder	0.176	0.221	CbGaD
Methotrimeprazine—DRD4—attention deficit hyperactivity disorder	0.0954	0.12	CbGaD
Methotrimeprazine—DRD3—attention deficit hyperactivity disorder	0.0823	0.103	CbGaD
Methotrimeprazine—DRD1—attention deficit hyperactivity disorder	0.0808	0.101	CbGaD
Methotrimeprazine—ADRA2A—attention deficit hyperactivity disorder	0.0751	0.0942	CbGaD
Methotrimeprazine—DRD2—attention deficit hyperactivity disorder	0.0569	0.0715	CbGaD
Methotrimeprazine—HTR2A—attention deficit hyperactivity disorder	0.044	0.0552	CbGaD
Methotrimeprazine—HTR2A—locus ceruleus—attention deficit hyperactivity disorder	0.00308	0.071	CbGeAlD
Methotrimeprazine—HTR2A—autonomic nervous system—attention deficit hyperactivity disorder	0.00164	0.0377	CbGeAlD
Methotrimeprazine—DRD5—forebrain—attention deficit hyperactivity disorder	0.00128	0.0295	CbGeAlD
Methotrimeprazine—ADRA1D—forebrain—attention deficit hyperactivity disorder	0.00103	0.0237	CbGeAlD
Methotrimeprazine—DRD1—forebrain—attention deficit hyperactivity disorder	0.000979	0.0225	CbGeAlD
Methotrimeprazine—DRD4—brain—attention deficit hyperactivity disorder	0.000807	0.0186	CbGeAlD
Methotrimeprazine—CHRM4—nervous system—attention deficit hyperactivity disorder	0.000798	0.0184	CbGeAlD
Methotrimeprazine—CHRM2—forebrain—attention deficit hyperactivity disorder	0.000789	0.0182	CbGeAlD
Methotrimeprazine—CHRM4—central nervous system—attention deficit hyperactivity disorder	0.000768	0.0177	CbGeAlD
Methotrimeprazine—HTR2C—forebrain—attention deficit hyperactivity disorder	0.00076	0.0175	CbGeAlD
Methotrimeprazine—DRD3—nervous system—attention deficit hyperactivity disorder	0.000742	0.0171	CbGeAlD
Methotrimeprazine—CHRM1—forebrain—attention deficit hyperactivity disorder	0.000718	0.0165	CbGeAlD
Methotrimeprazine—DRD3—central nervous system—attention deficit hyperactivity disorder	0.000714	0.0165	CbGeAlD
Methotrimeprazine—DRD5—nervous system—attention deficit hyperactivity disorder	0.000695	0.016	CbGeAlD
Methotrimeprazine—DRD5—central nervous system—attention deficit hyperactivity disorder	0.000669	0.0154	CbGeAlD
Methotrimeprazine—CHRM2—cardiovascular system—attention deficit hyperactivity disorder	0.000667	0.0154	CbGeAlD
Methotrimeprazine—DRD1—midbrain—attention deficit hyperactivity disorder	0.000646	0.0149	CbGeAlD
Methotrimeprazine—CHRM3—forebrain—attention deficit hyperactivity disorder	0.000642	0.0148	CbGeAlD
Methotrimeprazine—CHRM5—nervous system—attention deficit hyperactivity disorder	0.000624	0.0144	CbGeAlD
Methotrimeprazine—CHRM4—brain—attention deficit hyperactivity disorder	0.00061	0.0141	CbGeAlD
Methotrimeprazine—CHRM1—cardiovascular system—attention deficit hyperactivity disorder	0.000607	0.014	CbGeAlD
Methotrimeprazine—CHRM5—central nervous system—attention deficit hyperactivity disorder	0.000601	0.0138	CbGeAlD
Methotrimeprazine—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.00059	0.0136	CbGeAlD
Methotrimeprazine—DRD2—forebrain—attention deficit hyperactivity disorder	0.000578	0.0133	CbGeAlD
Methotrimeprazine—ADRA1B—nervous system—attention deficit hyperactivity disorder	0.00057	0.0131	CbGeAlD
Methotrimeprazine—DRD3—brain—attention deficit hyperactivity disorder	0.000567	0.0131	CbGeAlD
Methotrimeprazine—ADRA1D—nervous system—attention deficit hyperactivity disorder	0.000558	0.0128	CbGeAlD
Methotrimeprazine—ADRA1B—central nervous system—attention deficit hyperactivity disorder	0.000549	0.0126	CbGeAlD
Methotrimeprazine—ADRA1D—central nervous system—attention deficit hyperactivity disorder	0.000537	0.0124	CbGeAlD
Methotrimeprazine—DRD5—brain—attention deficit hyperactivity disorder	0.000531	0.0122	CbGeAlD
Methotrimeprazine—DRD1—nervous system—attention deficit hyperactivity disorder	0.000531	0.0122	CbGeAlD
Methotrimeprazine—DRD1—central nervous system—attention deficit hyperactivity disorder	0.000511	0.0118	CbGeAlD
Methotrimeprazine—HTR2C—midbrain—attention deficit hyperactivity disorder	0.000502	0.0116	CbGeAlD
Methotrimeprazine—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000499	0.0115	CbGeAlD
Methotrimeprazine—CHRM5—brain—attention deficit hyperactivity disorder	0.000477	0.011	CbGeAlD
Methotrimeprazine—HRH1—forebrain—attention deficit hyperactivity disorder	0.000457	0.0105	CbGeAlD
Methotrimeprazine—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000449	0.0103	CbGeAlD
Methotrimeprazine—ADRA1B—brain—attention deficit hyperactivity disorder	0.000436	0.01	CbGeAlD
Methotrimeprazine—CHRM2—nervous system—attention deficit hyperactivity disorder	0.000428	0.00987	CbGeAlD
Methotrimeprazine—ADRA1D—brain—attention deficit hyperactivity disorder	0.000426	0.00982	CbGeAlD
Methotrimeprazine—HTR2C—nervous system—attention deficit hyperactivity disorder	0.000413	0.00951	CbGeAlD
Methotrimeprazine—CHRM2—central nervous system—attention deficit hyperactivity disorder	0.000412	0.0095	CbGeAlD
Methotrimeprazine—DRD1—brain—attention deficit hyperactivity disorder	0.000406	0.00936	CbGeAlD
Methotrimeprazine—HTR2C—central nervous system—attention deficit hyperactivity disorder	0.000397	0.00916	CbGeAlD
Methotrimeprazine—CHRM1—nervous system—attention deficit hyperactivity disorder	0.00039	0.00898	CbGeAlD
Methotrimeprazine—DRD2—midbrain—attention deficit hyperactivity disorder	0.000382	0.0088	CbGeAlD
Methotrimeprazine—HTR2A—forebrain—attention deficit hyperactivity disorder	0.000381	0.00879	CbGeAlD
Methotrimeprazine—CHRM1—central nervous system—attention deficit hyperactivity disorder	0.000375	0.00865	CbGeAlD
Methotrimeprazine—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000371	0.00855	CbGeAlD
Methotrimeprazine—CYP2E1—cardiovascular system—attention deficit hyperactivity disorder	0.000371	0.00855	CbGeAlD
Methotrimeprazine—CHRM3—nervous system—attention deficit hyperactivity disorder	0.000349	0.00804	CbGeAlD
Methotrimeprazine—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.000347	0.008	CbGeAlD
Methotrimeprazine—CHRM3—central nervous system—attention deficit hyperactivity disorder	0.000336	0.00774	CbGeAlD
Methotrimeprazine—CHRM2—brain—attention deficit hyperactivity disorder	0.000327	0.00754	CbGeAlD
Methotrimeprazine—HTR2A—cardiovascular system—attention deficit hyperactivity disorder	0.000322	0.00743	CbGeAlD
Methotrimeprazine—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.00032	0.00738	CbGeAlD
Methotrimeprazine—HTR2C—brain—attention deficit hyperactivity disorder	0.000315	0.00727	CbGeAlD
Methotrimeprazine—DRD2—nervous system—attention deficit hyperactivity disorder	0.000314	0.00723	CbGeAlD
Methotrimeprazine—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000308	0.0071	CbGeAlD
Methotrimeprazine—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000305	0.00703	CbGeAlD
Methotrimeprazine—DRD2—central nervous system—attention deficit hyperactivity disorder	0.000302	0.00696	CbGeAlD
Methotrimeprazine—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000301	0.00694	CbGeAlD
Methotrimeprazine—CHRM1—brain—attention deficit hyperactivity disorder	0.000298	0.00686	CbGeAlD
Methotrimeprazine—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000296	0.00682	CbGeAlD
Methotrimeprazine—DRD2—cerebellum—attention deficit hyperactivity disorder	0.000295	0.00681	CbGeAlD
Methotrimeprazine—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000294	0.00677	CbGeAlD
Methotrimeprazine—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000287	0.00662	CbGeAlD
Methotrimeprazine—CHRM3—brain—attention deficit hyperactivity disorder	0.000267	0.00614	CbGeAlD
Methotrimeprazine—HTR2A—midbrain—attention deficit hyperactivity disorder	0.000252	0.0058	CbGeAlD
Methotrimeprazine—HRH1—nervous system—attention deficit hyperactivity disorder	0.000248	0.00571	CbGeAlD
Methotrimeprazine—ADRA1A—brain—attention deficit hyperactivity disorder	0.000245	0.00564	CbGeAlD
Methotrimeprazine—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000243	0.00561	CbGeAlD
Methotrimeprazine—Diltiazem—CACNA1C—attention deficit hyperactivity disorder	0.000242	0.0403	CrCbGaD
Methotrimeprazine—DRD2—brain—attention deficit hyperactivity disorder	0.00024	0.00553	CbGeAlD
Methotrimeprazine—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000239	0.0055	CbGeAlD
Methotrimeprazine—CYP2E1—nervous system—attention deficit hyperactivity disorder	0.000238	0.00549	CbGeAlD
Methotrimeprazine—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000234	0.0054	CbGeAlD
Methotrimeprazine—ADRA2C—brain—attention deficit hyperactivity disorder	0.000233	0.00537	CbGeAlD
Methotrimeprazine—CYP2E1—central nervous system—attention deficit hyperactivity disorder	0.000229	0.00528	CbGeAlD
Methotrimeprazine—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000229	0.00528	CbGeAlD
Methotrimeprazine—CYP2E1—cerebellum—attention deficit hyperactivity disorder	0.000224	0.00516	CbGeAlD
Methotrimeprazine—Acetophenazine—DRD1—attention deficit hyperactivity disorder	0.000219	0.0366	CrCbGaD
Methotrimeprazine—HTR2A—nervous system—attention deficit hyperactivity disorder	0.000207	0.00477	CbGeAlD
Methotrimeprazine—HTR2A—central nervous system—attention deficit hyperactivity disorder	0.000199	0.00459	CbGeAlD
Methotrimeprazine—HTR2A—cerebellum—attention deficit hyperactivity disorder	0.000195	0.00449	CbGeAlD
Methotrimeprazine—Propericiazine—DRD1—attention deficit hyperactivity disorder	0.000194	0.0323	CrCbGaD
Methotrimeprazine—HRH1—brain—attention deficit hyperactivity disorder	0.000189	0.00437	CbGeAlD
Methotrimeprazine—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.000189	0.00435	CbGeAlD
Methotrimeprazine—ADRA2A—brain—attention deficit hyperactivity disorder	0.000186	0.00429	CbGeAlD
Methotrimeprazine—CYP2E1—brain—attention deficit hyperactivity disorder	0.000182	0.00419	CbGeAlD
Methotrimeprazine—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.000182	0.00418	CbGeAlD
Methotrimeprazine—Propericiazine—ADRA2A—attention deficit hyperactivity disorder	0.00018	0.03	CrCbGaD
Methotrimeprazine—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.000177	0.00409	CbGeAlD
Methotrimeprazine—HTR2A—brain—attention deficit hyperactivity disorder	0.000158	0.00365	CbGeAlD
Methotrimeprazine—Acetophenazine—DRD2—attention deficit hyperactivity disorder	0.000155	0.0258	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD5—attention deficit hyperactivity disorder	0.00015	0.025	CrCbGaD
Methotrimeprazine—CYP2D6—brain—attention deficit hyperactivity disorder	0.000144	0.00332	CbGeAlD
Methotrimeprazine—Triflupromazine—DRD1—attention deficit hyperactivity disorder	0.000135	0.0224	CrCbGaD
Methotrimeprazine—Acepromazine—DRD1—attention deficit hyperactivity disorder	0.000124	0.0208	CrCbGaD
Methotrimeprazine—Thioproperazine—DRD1—attention deficit hyperactivity disorder	0.000122	0.0203	CrCbGaD
Methotrimeprazine—Mesoridazine—DRD3—attention deficit hyperactivity disorder	0.00012	0.0201	CrCbGaD
Methotrimeprazine—Pipotiazine—DRD1—attention deficit hyperactivity disorder	0.00012	0.02	CrCbGaD
Methotrimeprazine—Propiomazine—DRD4—attention deficit hyperactivity disorder	0.000118	0.0196	CrCbGaD
Methotrimeprazine—Prochlorperazine—DRD3—attention deficit hyperactivity disorder	0.000117	0.0194	CrCbGaD
Methotrimeprazine—Cyamemazine—HTR2A—attention deficit hyperactivity disorder	0.000106	0.0176	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD3—attention deficit hyperactivity disorder	0.000105	0.0176	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD1—attention deficit hyperactivity disorder	0.000103	0.0173	CrCbGaD
Methotrimeprazine—Propiomazine—DRD1—attention deficit hyperactivity disorder	9.95e-05	0.0166	CrCbGaD
Methotrimeprazine—Fluphenazine—ADRA2A—attention deficit hyperactivity disorder	9.61e-05	0.016	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD3—attention deficit hyperactivity disorder	9.6e-05	0.016	CrCbGaD
Methotrimeprazine—Triflupromazine—DRD2—attention deficit hyperactivity disorder	9.48e-05	0.0158	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD1—attention deficit hyperactivity disorder	9.42e-05	0.0157	CrCbGaD
Methotrimeprazine—Thioridazine—DRD1—attention deficit hyperactivity disorder	8.91e-05	0.0149	CrCbGaD
Methotrimeprazine—Clomipramine—ADRA2A—attention deficit hyperactivity disorder	8.79e-05	0.0147	CrCbGaD
Methotrimeprazine—Acepromazine—DRD2—attention deficit hyperactivity disorder	8.78e-05	0.0146	CrCbGaD
Methotrimeprazine—Promazine—DRD4—attention deficit hyperactivity disorder	8.71e-05	0.0145	CrCbGaD
Methotrimeprazine—Thioproperazine—DRD2—attention deficit hyperactivity disorder	8.58e-05	0.0143	CrCbGaD
Methotrimeprazine—Pipotiazine—DRD2—attention deficit hyperactivity disorder	8.44e-05	0.0141	CrCbGaD
Methotrimeprazine—Mesoridazine—DRD2—attention deficit hyperactivity disorder	8.33e-05	0.0139	CrCbGaD
Methotrimeprazine—Thioridazine—ADRA2A—attention deficit hyperactivity disorder	8.28e-05	0.0138	CrCbGaD
Methotrimeprazine—Trimipramine—SLC6A3—attention deficit hyperactivity disorder	8.25e-05	0.0138	CrCbGaD
Methotrimeprazine—Perphenazine—DRD1—attention deficit hyperactivity disorder	8.18e-05	0.0136	CrCbGaD
Methotrimeprazine—Trimipramine—ADRA2A—attention deficit hyperactivity disorder	8.09e-05	0.0135	CrCbGaD
Methotrimeprazine—Prochlorperazine—DRD2—attention deficit hyperactivity disorder	8.06e-05	0.0134	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD4—attention deficit hyperactivity disorder	7.67e-05	0.0128	CrCbGaD
Methotrimeprazine—Perphenazine—ADRA2A—attention deficit hyperactivity disorder	7.6e-05	0.0127	CrCbGaD
Methotrimeprazine—Promazine—DRD1—attention deficit hyperactivity disorder	7.37e-05	0.0123	CrCbGaD
Methotrimeprazine—Fluphenazine—DRD2—attention deficit hyperactivity disorder	7.29e-05	0.0122	CrCbGaD
Methotrimeprazine—Propiomazine—DRD2—attention deficit hyperactivity disorder	7.02e-05	0.0117	CrCbGaD
Methotrimeprazine—Promazine—ADRA2A—attention deficit hyperactivity disorder	6.85e-05	0.0114	CrCbGaD
Methotrimeprazine—Acepromazine—HTR2A—attention deficit hyperactivity disorder	6.78e-05	0.0113	CrCbGaD
Methotrimeprazine—Clomipramine—SLC6A4—attention deficit hyperactivity disorder	6.71e-05	0.0112	CrCbGaD
Methotrimeprazine—Chlorprothixene—DRD2—attention deficit hyperactivity disorder	6.64e-05	0.0111	CrCbGaD
Methotrimeprazine—Thioproperazine—HTR2A—attention deficit hyperactivity disorder	6.63e-05	0.0111	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD3—attention deficit hyperactivity disorder	6.61e-05	0.011	CrCbGaD
Methotrimeprazine—Pipotiazine—HTR2A—attention deficit hyperactivity disorder	6.52e-05	0.0109	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD1—attention deficit hyperactivity disorder	6.49e-05	0.0108	CrCbGaD
Methotrimeprazine—Mesoridazine—HTR2A—attention deficit hyperactivity disorder	6.44e-05	0.0107	CrCbGaD
Methotrimeprazine—Thioridazine—DRD2—attention deficit hyperactivity disorder	6.28e-05	0.0105	CrCbGaD
Methotrimeprazine—Trimipramine—SLC6A4—attention deficit hyperactivity disorder	6.17e-05	0.0103	CrCbGaD
Methotrimeprazine—Trimipramine—DRD2—attention deficit hyperactivity disorder	6.14e-05	0.0102	CrCbGaD
Methotrimeprazine—Imipramine—SLC6A3—attention deficit hyperactivity disorder	6.12e-05	0.0102	CrCbGaD
Methotrimeprazine—Chlorpromazine—ADRA2A—attention deficit hyperactivity disorder	6.03e-05	0.0101	CrCbGaD
Methotrimeprazine—Promethazine—DRD2—attention deficit hyperactivity disorder	5.91e-05	0.00985	CrCbGaD
Methotrimeprazine—Trifluoperazine—DRD2—attention deficit hyperactivity disorder	5.83e-05	0.00972	CrCbGaD
Methotrimeprazine—Perphenazine—DRD2—attention deficit hyperactivity disorder	5.77e-05	0.00962	CrCbGaD
Methotrimeprazine—Fluphenazine—HTR2A—attention deficit hyperactivity disorder	5.64e-05	0.0094	CrCbGaD
Methotrimeprazine—Propiomazine—HTR2A—attention deficit hyperactivity disorder	5.42e-05	0.00904	CrCbGaD
Methotrimeprazine—Promazine—DRD2—attention deficit hyperactivity disorder	5.2e-05	0.00867	CrCbGaD
Methotrimeprazine—Clomipramine—HTR2A—attention deficit hyperactivity disorder	5.15e-05	0.0086	CrCbGaD
Methotrimeprazine—Chlorprothixene—HTR2A—attention deficit hyperactivity disorder	5.13e-05	0.00856	CrCbGaD
Methotrimeprazine—Thioridazine—HTR2A—attention deficit hyperactivity disorder	4.86e-05	0.0081	CrCbGaD
Methotrimeprazine—Trimipramine—HTR2A—attention deficit hyperactivity disorder	4.74e-05	0.00791	CrCbGaD
Methotrimeprazine—Imipramine—SLC6A4—attention deficit hyperactivity disorder	4.58e-05	0.00763	CrCbGaD
Methotrimeprazine—Chlorpromazine—DRD2—attention deficit hyperactivity disorder	4.57e-05	0.00763	CrCbGaD
Methotrimeprazine—Promethazine—HTR2A—attention deficit hyperactivity disorder	4.57e-05	0.00761	CrCbGaD
Methotrimeprazine—Imipramine—DRD2—attention deficit hyperactivity disorder	4.55e-05	0.00759	CrCbGaD
Methotrimeprazine—Trifluoperazine—HTR2A—attention deficit hyperactivity disorder	4.51e-05	0.00751	CrCbGaD
Methotrimeprazine—Perphenazine—HTR2A—attention deficit hyperactivity disorder	4.46e-05	0.00743	CrCbGaD
Methotrimeprazine—Promazine—HTR2A—attention deficit hyperactivity disorder	4.02e-05	0.0067	CrCbGaD
Methotrimeprazine—Chlorpromazine—HTR2A—attention deficit hyperactivity disorder	3.54e-05	0.0059	CrCbGaD
Methotrimeprazine—Imipramine—HTR2A—attention deficit hyperactivity disorder	3.52e-05	0.00586	CrCbGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	9.56e-06	6.22e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	9.53e-06	6.2e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.5e-06	6.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	9.42e-06	6.13e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.41e-06	6.12e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	9.37e-06	6.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	9.37e-06	6.09e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.29e-06	6.05e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.29e-06	6.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	9.29e-06	6.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.15e-06	5.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	9.12e-06	5.93e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	9.08e-06	5.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—TPH2—attention deficit hyperactivity disorder	9.07e-06	5.9e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.07e-06	5.9e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.07e-06	5.9e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.05e-06	5.89e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	9.02e-06	5.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	9.02e-06	5.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	9.02e-06	5.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.99e-06	5.85e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.97e-06	5.84e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—DPYD—attention deficit hyperactivity disorder	8.92e-06	5.81e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.9e-06	5.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.88e-06	5.78e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.86e-06	5.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	8.86e-06	5.76e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.86e-06	5.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.74e-06	5.68e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.74e-06	5.68e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	8.74e-06	5.68e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.71e-06	5.66e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.67e-06	5.64e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.64e-06	5.62e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.59e-06	5.59e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.55e-06	5.56e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.48e-06	5.52e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.44e-06	5.49e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.44e-06	5.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.43e-06	5.48e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.39e-06	5.46e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.37e-06	5.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	8.32e-06	5.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.32e-06	5.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	8.3e-06	5.4e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.3e-06	5.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	8.25e-06	5.37e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.22e-06	5.35e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	8.19e-06	5.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	8.19e-06	5.33e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.12e-06	5.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.12e-06	5.28e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.12e-06	5.28e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	8.05e-06	5.24e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	8.01e-06	5.21e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.97e-06	5.19e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.9e-06	5.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.89e-06	5.13e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.87e-06	5.12e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.86e-06	5.11e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.84e-06	5.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.83e-06	5.1e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.8e-06	5.07e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.74e-06	5.04e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.73e-06	5.03e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	7.73e-06	5.03e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.71e-06	5.02e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.65e-06	4.98e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	7.64e-06	4.97e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.64e-06	4.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.64e-06	4.97e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	7.64e-06	4.97e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.62e-06	4.95e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.61e-06	4.95e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	7.6e-06	4.94e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.58e-06	4.93e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.57e-06	4.92e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.53e-06	4.9e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	7.52e-06	4.89e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.51e-06	4.89e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.49e-06	4.87e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.46e-06	4.85e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.39e-06	4.81e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	7.37e-06	4.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.37e-06	4.79e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.33e-06	4.77e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.31e-06	4.76e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	7.25e-06	4.72e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.25e-06	4.72e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.21e-06	4.69e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.11e-06	4.63e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.11e-06	4.63e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7.11e-06	4.63e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	7.11e-06	4.62e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	7.1e-06	4.62e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	7.04e-06	4.58e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	7.03e-06	4.57e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	7e-06	4.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.99e-06	4.55e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.98e-06	4.54e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.98e-06	4.54e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.96e-06	4.53e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.93e-06	4.51e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.9e-06	4.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.9e-06	4.49e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.87e-06	4.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.85e-06	4.46e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.85e-06	4.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	6.85e-06	4.45e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.82e-06	4.44e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.74e-06	4.39e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.7e-06	4.36e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.69e-06	4.35e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	6.66e-06	4.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.65e-06	4.33e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.63e-06	4.32e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.62e-06	4.31e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.58e-06	4.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	6.57e-06	4.27e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.56e-06	4.27e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.54e-06	4.26e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.53e-06	4.25e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.52e-06	4.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.52e-06	4.24e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.46e-06	4.2e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.45e-06	4.2e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	6.44e-06	4.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.44e-06	4.19e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.42e-06	4.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	6.42e-06	4.18e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	6.36e-06	4.14e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	6.34e-06	4.12e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.34e-06	4.12e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.32e-06	4.11e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.3e-06	4.1e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.24e-06	4.06e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	6.22e-06	4.05e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.22e-06	4.04e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	6.21e-06	4.04e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6.17e-06	4.01e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	6.16e-06	4.01e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.12e-06	3.98e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.11e-06	3.98e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.1e-06	3.97e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.08e-06	3.96e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.06e-06	3.94e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	6.02e-06	3.92e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	6.01e-06	3.91e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	6e-06	3.9e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.99e-06	3.9e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	5.99e-06	3.89e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.92e-06	3.85e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.92e-06	3.85e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.91e-06	3.84e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.91e-06	3.84e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.89e-06	3.83e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.87e-06	3.82e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.84e-06	3.8e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.82e-06	3.79e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.82e-06	3.78e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.82e-06	3.78e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.81e-06	3.78e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.8e-06	3.77e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.79e-06	3.77e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	5.78e-06	3.76e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.77e-06	3.76e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.75e-06	3.74e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.74e-06	3.73e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.72e-06	3.72e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.72e-06	3.72e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.7e-06	3.71e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	5.7e-06	3.71e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.65e-06	3.67e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.63e-06	3.66e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.61e-06	3.65e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	5.56e-06	3.62e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.53e-06	3.6e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—COMT—attention deficit hyperactivity disorder	5.5e-06	3.58e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—MAOA—attention deficit hyperactivity disorder	5.46e-06	3.55e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	5.42e-06	3.53e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.42e-06	3.53e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	5.39e-06	3.51e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.36e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.35e-06	3.48e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	5.34e-06	3.47e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	5.33e-06	3.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.33e-06	3.47e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.31e-06	3.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.3e-06	3.45e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.26e-06	3.42e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	5.25e-06	3.41e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	5.23e-06	3.4e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.05e-06	3.29e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	5.04e-06	3.28e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	5.01e-06	3.26e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.98e-06	3.24e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.98e-06	3.24e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.96e-06	3.23e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	4.87e-06	3.17e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	4.63e-06	3.01e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	4.6e-06	2.99e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	4.59e-06	2.99e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.59e-06	2.99e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	4.52e-06	2.94e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.5e-06	2.93e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.34e-06	2.82e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.32e-06	2.81e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.2e-06	2.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.2e-06	2.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	4.14e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.13e-06	2.69e-05	CbGpPWpGaD
Methotrimeprazine—DRD5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	4.03e-06	2.62e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.81e-06	2.48e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.74e-06	2.44e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.73e-06	2.43e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.72e-06	2.42e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.68e-06	2.4e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.67e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.67e-06	2.39e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.5e-06	2.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	3.41e-06	2.22e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.29e-06	2.14e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.26e-06	2.12e-05	CbGpPWpGaD
Methotrimeprazine—DRD4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.97e-06	1.93e-05	CbGpPWpGaD
Methotrimeprazine—CHRM4—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.93e-06	1.91e-05	CbGpPWpGaD
Methotrimeprazine—CHRM5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.81e-06	1.83e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	2.78e-06	1.81e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	2.76e-06	1.8e-05	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	2.68e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—DRD1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.68e-06	1.74e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	2.66e-06	1.73e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1D—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.64e-06	1.72e-05	CbGpPWpGaD
Methotrimeprazine—DRD3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.64e-06	1.72e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.38e-06	1.55e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Metabolism—EP300—attention deficit hyperactivity disorder	2.36e-06	1.53e-05	CbGpPWpGaD
Methotrimeprazine—HTR2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.29e-06	1.49e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.23e-06	1.45e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.19e-06	1.43e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	2.16e-06	1.41e-05	CbGpPWpGaD
Methotrimeprazine—DRD2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.02e-06	1.31e-05	CbGpPWpGaD
Methotrimeprazine—HTR2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.99e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	1.99e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.98e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.98e-06	1.29e-05	CbGpPWpGaD
Methotrimeprazine—CHRM3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.97e-06	1.28e-05	CbGpPWpGaD
Methotrimeprazine—CHRM2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.95e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.95e-06	1.27e-05	CbGpPWpGaD
Methotrimeprazine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.81e-06	1.18e-05	CbGpPWpGaD
Methotrimeprazine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.41e-06	9.17e-06	CbGpPWpGaD
Methotrimeprazine—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.19e-06	7.77e-06	CbGpPWpGaD
